Download PDF

Other users also viewed these articles

Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis Francisco Rodríguez-Moranta; Federico Argüelles-Arias; Joaquín Hinojosa del Val; Marisa Iborra Colomino; M. Dolores Martín-Arranz; Luis Menchén Viso; Fernando Muñoz Núñez; Elena Ricart Gómez; José Germán Sánchez-Hernández; Teresa Valdés-Delgado; Jordi Guardiola Capón; Manuel Barreiro-de Acosta; Míriam Mañosa Ciria; Yamile Zabana Abdo; Ana Gutiérrez Casbas;
Gastroenterol Hepatol. 2024;47:522-52
Body mass index does not influence loss of response to tumor necrosis factor inhibitors in Crohn's disease Carla Bortolin Fonseca; Roberta Petry; Luciana Harlacher; Laryssa Hanauer; Carlos Fernando Magalhães Francesconi; Paulo Gustavo Kotze; Cristina Flores;
Gastroenterol Hepatol. 2025;48:
Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease Javier Lucas Ramos; Cristina Suárez Ferrer; Joaquín Poza Cordón; María Sánchez Azofra; Jose Luis Rueda García; Eduardo Martin Arranz; Jorge Yebra Carmona; Irene Andaluz García; Maria Dolores Martín Arranz;
Gastroenterol Hepatol. 2021;44:337-45